Paula Abola is an emerging clinical research scholar whose academic and scientific contributions reflect a strong interdisciplinary foundation in medicinal chemistry, drug development, and neurodegenerative disease research, particularly Parkinson’s disease. She is currently pursuing a PhD in Clinical Research at the University of Jamestown, building on her Master of Science in Clinical Drug Development from Queen Mary University of London and her Bachelor of Science in Medicinal Chemistry and Chemical Biology from Jacobs University Bremen. Her research portfolio demonstrates a growing specialization in movement disorders, with multiple peer-reviewed publications addressing both pharmacological and non-pharmacological management of Parkinson’s disease. Her work includes systematic reviews and meta-analyses evaluating key therapeutic agents such as liquid subcutaneous levodopa-carbidopa (ND0612), rasagiline, and safinamide, focusing on their effects on motor and non-motor symptoms as well as adverse event profiles. Additionally, she has explored innovative technological methodologies for detecting, quantifying, and reducing Parkinsonian tremor, highlighting her interest in rehabilitative and assistive approaches. Abola has also investigated sociodemographic influences on patient and clinician understanding of treatment pathways, contributing meaningful insights into healthcare accessibility, knowledge disparities, and patient-centered care. Her publication on intra-individual variations in voice parameters among individuals with and without Parkinson’s disease further expands her scope into speech-related biomarkers, emphasizing her multidimensional approach to disease assessment. Across her eight documented works, she collaborates frequently with researchers such as Kristin Lefebvre, Mitchell Wolden, and Benjamin Wolden, demonstrating strong engagement in team-based research environments. Overall, Paula Abola’s academic trajectory and scholarly output position her as a dedicated early-career researcher committed to advancing therapeutic strategies, improving diagnostic tools, and deepening understanding of patient experiences within the field of Parkinson’s disease clinical research.
Profile: ORCID
Featured Publications
-
Abola, P., Lefebvre, K., & Wolden, M. (2025). Influence of sociodemographic variables on patient and practitioner knowledge of pharmacological management options for Parkinson’s disease. American Journal of Medical and Clinical Research & Reviews, 2025.
-
Abola, P., Lefebvre, K. (2025). Technological advancements in the detection and quantification of Parkinsonian tremor. Topics in Geriatric Rehabilitation, July 2025.
-
Abola, P., Wolden, M. (2025). Intra-individual variations in voice variables among individuals with and without Parkinson’s disease. Cureus, March 29, 2025.
-
Abola, P., Wolden, M., & Lefebvre, K. (2024). Liquid subcutaneous levodopa-carbidopa ND0612 effects on motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.
-
Abola, P., Wolden, M. (2024). Monoamine oxidase-B inhibitor rasagiline effects on motor and non-motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.
Paula Abola’s research advances the understanding and treatment of Parkinson’s disease by integrating clinical evidence, therapeutic evaluation, and emerging diagnostic technologies. Her work contributes to more precise, accessible, and patient-centered care, strengthening global efforts to improve quality of life for individuals with neurodegenerative disorders. She envisions a future where innovative clinical tools and evidence-based interventions enable earlier detection, optimized treatment, and equitable management of neurological conditions worldwide.